New studies suggest Parkinson’s may begin in the gut, spread to brain

Parkinson’s may not always start in the brain. A growing body of research has pointed to a body-first form of the disease in which misfolded alpha-synuclein appears in the gastrointestinal tract and may travel toward the brain through the vagus nerve over years, even decades. That shift matters because Parkinson’s is already a major and growing burden: more than 10 million people worldwide are living with it, about 1.1 million in the United States, and nearly 90,000 Americans are diagnosed each year.

The scale is rising fast. The Parkinson’s Foundation says the U.S. total is expected to reach 1.2 million by 2030. The World Health Organization says global prevalence doubled in the past 25 years, and Parkinson’s caused 5.8 million disability-adjusted life years in 2019, an 81% increase since 2000. Beyond the motor symptoms most people recognize, WHO lists slow movement, tremor, rigidity, trouble walking and imbalance, along with cognitive impairment, sleep disorders, pain and sensory disturbances.

The gut-brain theory has built momentum through a series of studies and reviews rather than one single breakthrough. A 2019 Nature article traced the idea back to post-mortem studies and emphasized the vagus nerve as a possible conduit. A 2020 Nature review highlighted gut-to-brain trafficking of misfolded alpha-synuclein and a newly described nigro-vagal pathway. More recent literature has framed Parkinson’s as potentially including a body-first subtype that begins in the gastrointestinal tract, then spreads to the brain, while also cautioning that not every case fits that pattern.

That caution matters. Researchers also have warned that some gastrointestinal problems in Parkinson’s may arise through brain-first, or top-down, mechanisms rather than starting in the gut. In other words, the disease may not be one process at all, but several pathways that end in similar symptoms. A 2024 Nature review added another piece of evidence, describing a study that found alpha-synuclein aggregates, a hallmark of Parkinson’s, in the gut and brain of people and animals with inflammatory bowel disease. That finding reinforced the idea that gut inflammation may help shape how the disease develops and progresses.

If the gut-brain hypothesis holds up, it could change when Parkinson’s is detected and where treatment begins. It would also help explain why digestive complaints often show up long before tremor or rigidity. For now, the evidence points to a disease that may begin farther from the brain than doctors once thought, with the vagus nerve, intestinal inflammation, altered intestinal permeability and gut microbes all under closer scrutiny.